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 Graphical abstract: 
 
 
 
 
Highlights: 
 Determination of essential trace elements - copper, manganese and zinc (Cu, Mn and 
Zn) in prescription food for special medical purposes (FSMPs) and in modified milk 
products (MMPs) available in Polish pharmacies for babies in the infancy period; 
 Investigation of discrepancies between declared and analysed levels of Cu, Mn  
and Zn levels in prescription FSMPs and in MMPs available in Polish pharmacies;  
 Safety assessment of the FSMPs and MMPs (one-time administration) in comparison 
to adequate intake of Cu, Mn and Zn established by the European Food Safety 
Authority (EFSA); 
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 Diet based on prescription FSMPs and MMPs available in Polish pharmacies does not 
fulfill the infant’s dietary need for Cu and Mn; 
 All products investigated in this study do not represent a health hazard to the 
consumer due to excess of Cu, Mn and Zn. 
 
 
Abstract: 
Background 
Prescription food for special medical purposes (FSMPs) and modified milk products (MMPs), 
available in pharmacies, are important for newborns and infants that are not breastfed. In the 
scientific literature there is a lack of comprehensive studies and corresponding safety 
assessment of the essential trace elements in these products.  
Objective 
The aim of this article was determination of Cu, Mn and Zn levels in the most frequently 
available prescription FSMPs (n = 6) and MMPs (n = 6) available in Polish pharmacies.  
Methods 
Flame absorption spectrometry (FAAS) following microwave induced digestion (concentrated 
nitric acid) was applied to determine the levels of the elements in the products.  
Results 
Our studies are based on a triple approach (1) the “raw results” of Cu, Mn and Zn levels 
(products in powdered form), (2) single intake - the level of each essential trace element 
consumed in one portion, (3) the daily intake depending on age and weight including 
comparison with Adequate Intake established by European Food Safety Authority.  
Conclusion 
The results show the occurrence of differences between the manufacturer’s declared 
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composition and the finished product for consumption. The prescription FSMPs in 
comparison to MMPs available in Polish pharmacies contain similar levels of Cu, Mn and Zn. 
Our results show additionally that all of the products do not represent a health hazard to the 
newborns and infants. This is a pioneer study in terms of the safety assessment, and quality of 
prescription FSMPs and MMPs available in Polish pharmacies from toxicological and 
nutritional point of view. 
 
 
Abbreviations: 
AI - Adequate Intake, Ars - Average Requirements (ARs), F AAS - flame atomic absorption 
spectrometry technique, bw - body weight, EFSA - European Food Safety Authority,  
EU - European Union; FCS - food contact substance, FSMPs - food for special medical 
purposes, IOM - Institute of Medicine; MMPs - modified milk products, n/a - not available, 
PRIs - Population Reference Intakes, WHO - World Health Organization, SD - standard 
deviation. 
 
 
Keywords: 
prescription food for special medical purposes; modified milk products; copper, manganase; 
zinc; toxicological analysis 
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 1. Introduction 
During the infancy period, breast milk, prescription food for special medical purposes 
(FSMPs) and modified milk products (MMPs) available in pharmacies and markets are the 
major source of essential trace elements for infants [1]. Despite the fact that the World Health 
Organization (WHO) recommends breastfeeding as the best feeding choice [2], prescription 
FSMPs and also MMPs available in pharmacies are a common alternative to breastfeeding. It 
should be emphasised that this alternative is sometimes a choice dictated by several types of 
allergies, diseases and/or dietary problems. Moreover, there are also other issues related to 
this possibility. For example, as was described by the Polish Center for Lactation Science, in 
Poland mothers want to feed their babies naturally – c.a. 98% of mothers begin to breastfeed 
their babies after childbirth. However, the number of breastfeeding mothers drops drastically 
to 46% in the first month after the birth of a baby [3]. Products available from pharmacies 
seem to be the most appropriate formulations with which to follow on from breast feeding. 
However, there is a lack of studies around the safety and quality of prescription FSMPs and 
MMPs available in pharmacies, with appropriate toxicological analysis.  
It is well known that adequate levels of essential trace elements in the diet of babies in the 
infancy period are essential for lifelong health and well-being. This is due to the fact that this 
period is characterised by a very high growth rate and microelemental requirements are more 
critical than in the later stages of growth [4]. It should be noted that essential trace elements 
are necessary for many various functions in the body, especially bone mineralization, 
enzymatic reactions and protection of cells and lipids in biological membranes. Toxicological 
aspects related to this topic are consequences of especially (1) low intake or reduced 
bioavailability of essential trace elements which causes impairment of body functions and (2) 
excessive levels associated with important potential toxic effects [5]. Unfortunately, essential 
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trace elements present in prescription FSMPs and MMPs available in pharmacies have 
received little attention or only limited toxicological consideration.  
Cu, Mn and Zn are major essential trace elements and have different and important 
biochemical functions in living organisms. Cu can be classified as a major essential trace 
element due to the wide range of enzymes that use this element as a co-factor. Hence, the 
symptoms of Cu deficiency are diverse [6], for example, scoliosis and scorbutic-like changes 
have been reported in copper-deficient infants and children [7]. On the other hand, an excess 
of this element has been recorded and shown to cause problems only under certain conditions, 
notably genetic disorders such as Wilson disease [8].  
Mn is also a major essential trace element because this element is an essential dietary 
mineral for mammals. It is a component of metalloenzymes such as superoxide dismutase, 
arginase and pyruvate carboxylase, and is involved in amino acid, lipid and carbohydrate 
metabolism [9]. The evidence of Mn deficiency in newborns and infants is poor – a specific 
deficiency syndrome has not been described in humans [10]. Hence, Mn deficiency is an 
important problem, but also important is an excess of this element. The symptoms of Mn 
toxicity can result in a permanent neurological disorder known as manganism [11]. 
Furthermore, oral exposure to manganese can also cause adverse health effects, which are 
similar to those observed by inhalation exposure [11]. It should also be noted that the level at 
which exposure to Mn is related to any toxicological effects has not been established 
especially for newborns and infants [11]. 
Undoubtedly, Zn is ubiquitous and one of the essential trace elements. This element takes 
part in many physiological functions and is ubiquitous within every cell in the body [12]. This 
is the reason why Zn deficiency is very important topic. On the other hand, chronicly high Zn 
intake can result in different diseases like copper deficiency as the results of antagonism of 
both elements [13]. 
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There is no doubt that safety assessment of trace elements and control studies about 
metallic impurities in milk-based products for babies are very important. In the scientific 
literature articles about determination of trace elements in milk-based products are very 
common, however most of investigated products are available in markets and approaches in 
safety assessment are insufficient. Hence, the justifications for undertaking the analysis of Cu, 
Mn and Zn content in prescription FSMPs and MMPs available in pharmacies for newborns 
and infants available in Polish pharmacies are (1) lack of studies about safety assessment of 
FSMPs and MMPs from pharmacies, (2) insufficient approaches in safety assessment, (3) lack 
of interpretation of obtained results from toxicological and nutritional point of view and (4) 
inadequate sensitivity and validation of the applied analytical technique. 
The analysis of these products requires the application of sensitive, selective and validated 
analytical techniques. In scientific articles about analysis of trace elements in milk-based 
products for babies, different analytical techniques are applied. However only three are 
commonly applied - (1) neutron activation analysis (NAA), (2) inductively coupled plasma 
mass spectrometry (ICP-MS) and the most common technique – (3) atomic absorption 
spectrometry (AAS). It is worth noting that high-resolution continuum source atomic 
absorption spectroscopy (HR-CS AAS) appears to be a good alternative for the determination 
of heavy metallic elements according to traditional AAS. However, in these studies we 
applied the well-known and accepted AAS technique with flame atomisation (F-AAS) due to 
its simplicity, availability and well-grounded analytical background. 
Hence, the aim of our article was the analysis of Cu, Mn and Zn content in prescription 
FSMPs (n = 6) and MMPs available in Polish pharmacies (n = 6) from a toxicological and 
dietary point of view. 
 
2. Material and methods 
AC
CE
PT
ED
 M
AN
US
CR
IPT
2.1. Reagents and materials 
In the preparation of all sample solutions, demineralized water (Millipore) and suprapure 
nitric acid (65%) at spectroscopic grade Merck (SupraPur, Darmstadt, Germany) were used. 
To avoid any metallic impurities/contamination at all stages of our study, all plastic and glass 
materials and equipment were previously treated in 0.5 mol/L nitric acid for 24 h and then 
rinsed using demineralized water. Certified standard solutions (1000 µg/L, Merck; for each 
element) and demineralized water were used for preparation of standard solutions. Acetylene 
(99.99%) was used in the atomization technique. Corn Flour, INCT-CF-3 (the Institute of 
Nuclear Chemistry and Technology Department of Analytical Chemistry) was used as the 
certified reference material (CRM). Additional information about the reference material is 
described in the supporting information (see Table S1).  
 
2.2. Samples  
2.2.1. Description of samples 
The twelve different pharmaceutical products, i.e. prescription FSMPs (n = 6) and MMPs 
(n = 6) were obtained in pharmacies in Poland (Kraków and Niepołomice). The choice of 
products was based on their availability in Polish pharmacies. Our research includes all of the 
products issued on prescription and available in Polish pharmacies since January 2019. It 
should be noted that our studies include only products available in pharmacies but not in 
markets, hence sample size cannot be extended. Based on our best knowledge this situation is 
very similar in other countries in European Union. The products dedicated to babies at 0 – 6 
months (initial milk formulas) were numbered as “1”. Similarly, the products dedicated to 
babies at 7-12 months (subsequent milk formulas) from the same manufacturer were 
numbered as “2”. Hence, twelve products – six FSMPs (A1, A2, B1, B2, C1 and C2) and six 
MMPs (D1, D2, E1, E2, F1 and F2) dedicated for newborns and infants were analysed. The 
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coding system of samples is given in the supporting information (see Table S2). The 
manufacturer’s declared level of analysed essential trace elements of each sample is shown in 
the supporting information (see Table S3).  
 
2.2.2. Sampling 
A representative amount from the original packaging of each FSMP or MMPs was 
collected. The sampling procedure was carried out using a single plastic spoon added to the 
product to avoid any possible metallic impurities. All samples were stored at room 
temperature in sterilised disposable containers made of plastic (containers for urine analysis 
from pharmacies). 
 
2.2.3. Pre-treatment of samples 
Prior to the measurements, samples were dried in an oven at 70° C in a ceramic crucible, of 
known weight, for 48 h. Weight consistency was checked after drying. The moisture content 
of the products under test (calculated from the mass difference prior to and after drying) was 
about 2.5%.  
 
2.3. Apparatus and applied methods 
All instrumental parameters are presented in the sections below and more details are 
described in the supplementary materials mentioned in the text. For better readability, the 
simplified workflow of analysis steps is illustrated in Fig. 1.  
 
 
Fig. 1. The basic workflow of the analysis of Cu, Mn and Zn in prescription FSMPs and 
modified milk products for babies in infancy period by the F-AAS. 
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 2.3.1. Digestion  
A microwave-assisted digestion procedure was applied in order to achieve a shorter 
digestion time. A microwave oven MDS 2000 (CEM USA) programmable for time and 
microwave power was applied. Approximately 300 mg of each sample was placed in 
microwave-assisted wet digestion vessels with 5.0 mL of nitric acid. The digestion step lasted 
about 0.5 h. The multi-stage digestion program is presented in the supporting information (see 
Table S4). After cooling, the resulting solutions (digests) were evaporated to semidried mass 
to remove excess acid, and then diluted up to 20 mL in volumetric flasks using demineralized 
water and kept as stock sample solutions. The sample solutions were stored at room 
temperature (20-22 °C) until determination of the metals. 
 
2.3.2. Determination of Cu, Mn and Zn 
All analyses were performed using a Perkin-Elmer 5100 ZL (CT, USA) atomic absorption 
spectrometer (AAS) with Zeeman background correction and with flame atomization (FA). 
Deuterium lamp background correction (Perkin-Elmer 5100 ZL, CT, USA) was applied. The 
important instrumental parameters are presented in the supporting information  
(see Table S5). 
 
 
2.3.3. Analytical calibration and quality control 
The linear range of the calibration curve reached from the detection limit up 0.0; 0.25; 0.5; 
1.0; 2.0; 3.0 mg/L for Cu, 0.0; 0.25; 0.5; 1.0; 2.0; 5.0 mg/L for Mn, and 0.0; 0.25; 0.5; 1.0; 
2.0; 3.0 for Zn mg/L, respectively. A good indicator of the linearity for AAS instrument for 
precision and accuracy of results is the correlation coefficient (R) [14]; all obtained R values 
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were acceptable, i.e. ≥ 0.998 (0.998 for Cu, 0.999 for Mn and 0.998 for Zn). 
The LODs were determined for Cu, Mn and Zn as 2.1 µg/L, 3.2 µg/L and 2.0 µg/L, 
respectively.  The recoveries obtained were 96.8.0 % for Cu, 98.2 % for Mn and 97.6% for 
Zn. The recoveries were calculated as the quotient of the determined level and the known 
amount of the determined element expressed as a percentage. 
Blank samples of ultrapure water were prepared to apply the same procedure as for the 
samples to assess possible impurities during sample preparation and analytical calibration 
step. All blanks contained negligible amounts of Cu, Mn and Zn. Newly prepared standard 
stock solutions were serially diluted and applied to obtain calibration functions.  
The confirmation of the quality control and validation of the applied methodology are 
previously described using the same methodology and apparatus – Cu [15], Mn [16] and Zn 
[17].  
 
2.3.4. Statistical analysis 
All measurements were performed in three replications. The mean, standard deviation (SD) 
and further calculations were made using Microsoft Office Excel 2016 for Windows.  
 
3. Results 
The Cu, Mn and Zn concentrations in the samples can be presented considering three 
approaches (1) the “raw results” - results of the dry weight, (2) values for one-time 
administration - including dilution in the finished product, (3) and the daily dose. This 
proposed approach is appropriate because it includes (1) information about the levels of 
essential trace elements in a concentrated product (powdered form) and allows the 
investigation of any discrepancies between declared and analyzed values; (2) single intake - 
the actual concentration of investigated essential trace elements consumed in one portion, (3) 
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daily dose - depending on age and body weight. 
 
3.1. Results of the dry weight (essential trace elements per kg of dried mass) 
The results of the dry weight of analysed samples are given in Table 1.  
 
Table 1. Concentrations of investigated essential trace elements: Cu, Mn and Zn in analysed 
samples (mg/kg); FSMPs - food for special medical purposes; MMPs – modified milk 
products; SD – standard deviation.  
 
The products are divided into groups related to the recommended age of product use. 
Results are given as a mean of each sample with standard deviation (SD) value. The 
determined essential trace elements were present in all of the samples. The concentration of 
Cu was in the range of 2.059 to 4.239 mg/kg, Mn concentration was in the range of 0.983 to 
4.043 mg/kg and Zn concentration was in the range 29.098 to 61.169 mg/kg. The mean values 
of the essential trace elements divided into prescription FSMPs and MMPs available in Polish 
pharmacies are shown in Figure 2. 
 
Fig. 2. The mean values of investigated essential trace elements divided in to prescription 
FSMPs and MMPs available in Polish pharmacies. 
 
The highest mean concentration was for Zn, and the lowest mean concentration was observed 
for Mn. Moreover, our results indicated that the prescription FSMPs contain similar levels of 
the essential trace elements under investigation when compared to MMPs available in Polish 
pharmacies. 
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3.2. One-time administration of investigated prescription FSMPs and modified milk products 
The calculated concentration in the amount of milk corresponds to one portion (appropriate 
number of spoons) dissolved in a precisely defined volume of water specified by the 
producer. The results of one-time administration of investigated prescription FSMPs and 
MMPs available in Polish pharmacies are given in Table 2., as mg/L of milk. 
 
Table 2. Concentrations of investigated essential trace elements: Cu, Mn and Zn including 
one-time administration (mg/L of milk); FSMPs - food for special medical purposes; MMPs – 
modified milk products. 
 
3.3. Daily dose due to age and body weight 
Proper complementary feeding including appropriate levels of essential trace elements is 
crucial for newborns and infants for optimal growth and development which is very 
individual and depends on many factors. However, all manufacturers place appropriate 
information on the packaging as a guide for the correct amounts of cool boiled water and milk 
in powder form to use. It is commonly known that the frequency of feeding depends on age 
(months) and body weight of the newborn or infant. Taking this into account the daily doses 
of the essential trace elements were calculated and presented in Table 3.  
 
 
Table 3. A daily dose of Cu, Mn and Zn in analysed samples (mg/kg bw/day). 
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4. Discussion 
4.1. Results of the dry weight (essential trace elements per kg of dried mass)  
It should be noted that prescription FSMPs and MMPs available in Polish pharmacies 
contribute significantly to Cu, Mn and Zn levels in newborns and infants. Generally, each 
producer presents the declared quantitative composition of each essential trace element in a 
given product and it is possible to obtain information on the compliance of the results with the 
declared values. Analysed and declared values of all essential trace elements in the samples 
are presented in supported materials (see Table S6).  
With respect to Cu, in most samples (8/12) declared values are higher than those 
determined in this study. There is no more than a 30% difference. However, most of the 
results indicate that the products do not meet the declared values and thus the product is not 
consistent with the description. Moreover, taking into account absorption – there exists a 
probability of deficiency of this essential trace element during application of these products 
(especially when diet of babies is based only on prescription FSMPs or MMPs available in 
Polish pharmacies. However, this probability should be considered minimal because there is 
no evidence of overt copper deficiency in the European population [6]. Of course, absence of 
Cu-deficiency across Europe in general does not mean that there are no local deficiencies, 
hence this aspect should be kept in mind.   
   Mn is very important from newborn’s and infant’s toxicological point of view [18-22], 
hence the appropriate level of this metal should be maintained. In all of the samples analysed 
the difference between the results obtained against the declared values are positive, hence in 
all samples levels of Mn are much higher than declared values. In three samples the Mn level 
is equal to or greater than twice the declared value (samples: C2, D2 and F2). It should also be 
noted that Mn levels in different types of milk products is very variable. 
There is no doubt that Zn is one of the most important essential trace element for newborns 
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and infants. It should be noted that of all the trace elements found in humans, only Fe is more 
abundant than Zn [12, 23-24]. Moreover, this indicates that inadequate dietary intake of Zn 
due inappropriate diet (low zinc levels) can lead to a real risk of Zn deficiency [12]. In all 
samples there are slight differences between the declared composition and the declared values 
(the differences do not exceed 20% except sample F 2). In seven samples the declared values 
are higher than determined.  
Additionally, our results provide valuable baseline data for other researchers for 
comparison of other kinds of prescription FSMPs and/or MMPs available in pharmacies. 
 
4.2. One-time administration of applied prescription FSMPs and MMPs available in Polish 
pharmacies 
The levels determined for these essential trace elements in the dry mass of the products are 
very important, especially for to safety and quality assessment. However, a more valuable 
measure for consumers is the actual amount of the essential trace elements in a single portion 
of final milk, as fed, because it can be valuable from the risk assessment point of view.  
The EU has so far set thresholds for intake levels of the heavy metals (Pb, Cd and Hg)  
[25-26]. However, for many other metals (including Cu, Mn, Zn) levels that lead to 
deficiencies and chronic or acute poisonings are known, but no explicit thresholds have yet 
been set. Hence, it is not possible to discuss our results in the context of risk assessment. 
However, our results can be valuable for other researchers and are necessary for further 
considerations. 
 
4.3. The daily dose   
In the EU the scientific opinions on dietary reference values for Cu, Mn and Zn are 
published by European Food Safety Authority (EFSA). Below we discuss the results for the 
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daily dose for each essential trace element separately.  
Due to the absence of appropriate biomarkers of Cu status and the limitations of available 
balance studies, the EFSA was unable to derive Average Requirements (ARs) and Population 
Reference Intakes (PRIs) for Cu. Hence, Adequate Intake (AIs) was derived based on mean 
observed intakes in several countries in the EU, given that there is no evidence of overt Cu 
deficiency in the European population [6]. For infants aged 7–11 months (based on results 
from four surveys in infants), an AI of 0.4 mg/day was established. The EFSA applied 
extrapolation by allometric scaling of estimated Cu intake in exclusively breastfed infants 
aged 0–6 months results in an estimated intake at 7–11 months of 0.36 mg/day, which 
supports the AI of 0.4 mg/day. It should be emphasized that AIs should not be interpreted as 
upper limit for the intake of the trace elements but as a target value. In comparison to our 
results, only results for infancy at 6 – 12 months (subsequent milk formulas marked as “2”) 
can be compared after calculations excluding mass of infants which consequently gives the 
following values: A2 – 0.415 mg/day; B2 – 0.185 mg/day; C2 – 0.225 mg/day; D2 – 0.236 
mg/day; E2 – 0.231 mg/day; and F2 – 0.272 mg/day. Only sample A2 is characterised by a 
similar value to AI (0.4 mg/day). In other products, the Cu level is approximately a half level 
of AI. It should be noted that these products represent the only source of the Cu, hence most 
products analysed do not contain enough Cu to achieve the recommended level of intake. 
Conversely, none of the investigated samples represents a health hazard to the consumer due 
to excess but there is a potential risk associated with deficiency of Cu in the diet.  
The estimated AI of Mn by EFSA is based on observed intakes of this essential trace 
element together with the absence of evidence of signs of deficiency. The respective AIs was 
established as 0.5 mg/day in infants aged 7-11 months [10]. Hence, in analogy to Cu, only 
results for infancy at 6 – 12 months (subsequent milk formulas marked as “2”) can be 
compared after calculations excluding mass of infants which consequently gives the following 
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values: A2 – 0.251 mg/day; B2 – 0.094 mg/day; C2 – 0.100 mg/day; D2 – 0.130 mg/day; E2 
– 0.078 mg/day; and F2 – 0.092 mg/day. In all products, the Mn level is below of AI (0,5 
mg/day). It should be noted that AI does not mean a requirement of nutrients - it is the median 
or average value of the intake of the population without deficiency. According to our findings, 
none of the investigated samples represents a health hazard to the consumer due to excess of 
Mn in the diet. Taking into account also fact that Mn requirement value and the symptoms of 
Mn deficiency are unknown it is not possible to made any expressions about the required 
amount of this element in the diet of babies. 
Concerning Zn, the Institute of Medicine (IOM) set an Adequate Intake (AI) of  
2.0 mg/day for infants aged 0 – 6 months [27]. Additionally, the estimated physiological zinc 
requirement for infants aged 7 to 11 months is 0.732 mg/day [27]. The obtained results can be 
compared after calculations excluding mass of infants in two age groups:  
 0 – 6 months:  A2 – 3.581 mg/day; B2 – 3.191 mg/day; C2 – 3.003 mg/day; D2 – 3.889 
mg/day; E2 – 2.578 mg/day; and F2 – 4.688 mg/day; 
 7 – 11 months: A2 – 5.142 mg/day; B2 – 2.619 mg/day; C2 – 3.418 mg/day; D2 – 4.108 
mg/day; E2 – 2.694 mg/day; and F2 – 5.750 mg/day. 
The results obtained for the first age group (0 – 6 months) exceed the value of AI (especially 
D2 and F2). On the other hand, the results for second age group (7 – 11 months) are much 
higher than the estimated physiological zinc requirement. However, most of the results 
indicate that the products do not meet the declared values, and thus the product is not 
consistent with the description. Taking into account fact that Zn does not accumulate in the 
body [12], the excess of Zn in the products analyzed is not a serious threat. Accordingly, none 
of the analysed products represent a health hazard for the newborns and infants due to excess 
and deficiency. 
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5. Conclusions 
For proper complementary feeding of babies in infancy period, the appropriate level of 
essential trace elements in prescription FSMPs or MMPs available in pharmacies is required. 
There is currently a dearth of published literature, in terms of toxicological aspects, around 
the essential trace elements Cu, Mn and Zn and in safety, risk and quality assessment of 
pharmaceutical products.  
Taking into account our raw results, there are slight differences between the declared 
composition and the declared values in all cases – in most samples (8/12) declared values are 
higher than determined. However, it can be also concluded that the prescription FSMPs in 
comparison to MMPs available in Polish pharmacies contain similar amounts of investigated 
essential trace elements. 
The results of one-time administration show that none of the analysed products represent a 
health hazard for the newborns and infants due to excess of Cu, Mn and Zn levels. It should 
be noted that the Cu levels (except sample A2) and Mn levels are all below of AI.  
Daily dose calculations (mg/kg bw/day) confirm that none of the products represent a 
health hazard due to excess of elements for babies in the infancy period. 
It can be concluded that our study confirms that a diet based on prescription FSMPs and 
MMPs available in Polish pharmacies, alone, does not fulfill, in most cases, the infant’s 
dietary need for Cu and Mn. All the analysed prescription FSMPs and MMPs do not represent 
a health hazard to the newborns and infants in relation to excess Cu, Mn and Zn levels. 
Moreover, our results could be valuable to other researchers to compare the results for other 
kind of prescription FSMPs and/or MMPs available in pharmacies from other countries. A 
broader study considering prescription FSMPs and MMPs available in pharmacies from other 
countries, would be valuable like previously described [28,29]. 
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 Fig. 1. The basic workflow of the analysis of Cu, Mn and Zn in prescription FSMPs and modified milk products for babies in infancy period by 
the F AAS. 
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 Fig. 2. The mean values of investigated essential trace elements divided in to prescription 
FSMPs and MMPs available in Polish pharmacies. 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Table 
 
Table 1. Concentrations of investigated essential trace elements: Cu, Mn and Zn in analysed 
samples (mg/kg). 
Sample 
Concentration [mg/kg] 
Cu Mn Zn 
No. Type Code Mean SD Mean SD Mean SD 
1. 
p
re
sc
ri
p
ti
o
n
 F
S
M
P
s 
A 1 3.542 0.207 4.043 0.497 36.539 2.955 
2. A 2 4.239 0.164 2.562 0.010 52.471 5.684 
3. B 1 3.293 0.211 1.055 0.120 35.451 1.535 
4. B 2 2.059 0.138 1.039 0.156 29.098 1.044 
5. C 1 2.317 0.160 0.983 0.087 33.366 0.723 
6. C 2 2.499 0.008 1.104 0.080 37.977 3.327 
7. 
M
M
P
s 
 
av
ai
ab
le
 i
n
 P
o
li
sh
 p
h
ar
m
ac
ie
s 
D 1 3.560 0.183 1.791 0.021 45.222 0.203 
8. D 2 2.747 0.197 1.515 0.056 47.765 2.953 
9. E 1 3.484 0.505 1.017 0.159 31.431 1.409 
10. E 2 2.816 0.573 0.951 0.032 32.857 1.752 
11. F 1 2.637 0.265 1.353 0.039 49.869 0.099 
12. F 2 2.891 1.159 0.985 0.326 61.169 2.459 
 
Applied acronyms: FSMPs - food for special medical purposes; MMPs – modified milk 
products; SD – standard deviation. 
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Table 2. Concentrations of investigated essential trace elements: Cu, Mn and Zn including 
one-time administration (mg/L of milk). 
 
Sample 
Cu concentration, mg/L 
Mn concentration, 
mg/L 
Zn concentration, mg/L 
No. Type Code Mean Mean Mean 
1. 
p
re
sc
ri
p
ti
o
n
 F
S
M
P
s 
A 1 0.579 0.660 5.968 
2. A 2 0.692 0.418 8.570 
3. B 1 0.494 0.158 5.318 
4. B2 0.309 0.156 4.365 
5. C 1 0.348 0.147 5.005 
6. C 2 0.375 0.166 5.697 
7. 
M
M
P
s 
 
av
ai
ab
le
 i
n
 P
o
li
sh
 p
h
ar
m
ac
ie
s 
D 1 0.510 0.257 6.482 
8. D 2 0.394 0.217 6.846 
9. E 1 0.476 0.139 4.296 
10. E 2 0.385 0.130 4.490 
11. F 1 0.413 0.212 7.813 
12. F 2 0.453 0.154 9.583 
 
Applied acronyms: FSMPs - food for special medical purposes; MMPs – modified milk 
products. 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Table 3. A daily dose of Cu, Mn and Zn in analysed samples (mg/kg bw/day). 
 
re
su
lt
s 
fo
r 
C
u
 
age 
approxima
te body 
weight 
[kg] 
samples 
prescription FSMPs MMPs available in Polish pharmacies 
A B C D E F 
0 – 2 
weeks 
< 3.0 – 3.5 
1 
0.11
6 
0.09
9 
1 
 
0.09
9 
0.08
5 
1 
0.07
0 
0.06
0 
1 
0.10
2 
0.08
7 
1 
0.09
5 
0.08
2 
1 
 
0.08
3 
0.07
1 
2 – 4 
weeks 
3.5 – 4.0 
0.09
9 
0.08
7 
0.08
5 
0.07
4 
0.06
0 
0.05
2 
0.08
7 
0.07
7 
0.08
2 
0.07
1 
0.07
1 
0.06
2 
4 – 8 
weeks 
4.0 – 5.0 
0.08
7 
0.06
9 
0.07
4 
0.05
9 
0.05
2 
0.04
2 
0.07
7 
0.06
1 
0.07
1 
0.05
7 
0.06
2 
0.05
0 
8 – 16 
weeks 
5.0 – 6.5 
0.06
9 
0.05
3 
0.05
9 
0.04
6 
0.04
2 
0.03
2 
0.06
1 
0.04
7 
0.05
7 
0.04
4 
0.05
0 
0.03
8 
4 – 6 
month
s 
> 6.5 
0.053 
0.046 0.032 0.047 0.044 0.038 
7 – 12 
month
s 
> 6.5 2 
0.064  
0.029 2 0.035 2 0.036 2 0.036 2 0.042 
re
su
lt
s 
fo
r 
M
n
 
age 
approxima
te body 
weight 
[kg] 
samples 
prescription FSMPs MMPs available in Polish pharmacies 
A B C D E F 
0 – 2 
weeks 
< 3.0 – 3.5 
1 
0.13
2 
0.11
3 
1 
 
0.03
2 
0.02
7 
1 
0.02
9 
0.02
5 
1 
0.05
1 
0.04
4 
1 
0.02
8 
0.02
4 
1 
 
0.04
2 
0.03
6 
2 – 4 
weeks 
3.5 – 4.0 
0.11
3 
0.09
9 
0.02
7 
0.02
4 
0.02
5 
0.02
2 
0.04
4 
0.03
9 
0.02
4 
0.02
1 
0.03
6 
0.03
2 
4 – 8 
weeks 
4.0 – 5.0 
0.09
9 
0.07
9 
0.02
4 
0.01
9 
0.02
2 
0.01
8 
0.03
9 
0.03
1 
0.02
1 
0.01
7 
0.03
2 
0.02
5 
8 – 16 
weeks 
5.0 – 6.5 
0.07
9 
0.06
1 
0.01
9 
0.01
5 
0.01
8 
0.01
4 
0.03
1 
0.02
4 
0.01
7 
0.01
3 
0.02
5 
0.02
0 
4 – 6 
month
s 
> 6.5 
0.061 
0.015 0.014 0.024 0.013 0.020 
7 – 12 
month
s 
> 6.5 2 
0.039  
0.014 2 0.015 2 0.020 2 0.012 2 0.014 
re
su
lt
s 
fo
r 
Z
n
 
age 
approxima
te body 
weight 
[kg] 
samples 
prescription FSMPs MMPs available in Polish pharmacies 
A B C D E F 
0 – 2 
weeks 
< 3.0 – 3.5 
1 
1.19
4 
1.02
3 
1 
 
1.06
4 
0.91
2 
1 
1.00
1 
0.85
8 
1 
1.29
6 
1.11
1 
1 
0.85
9 
0.73
6 
1 
 
1.56
3 
1.33
9 
2 – 4 
weeks 
3.5 – 4.0 
1.02
3 
0.89
5 
0.91
2 
0.79
8 
0.85
8 
0.75
1 
1.11
1 
0.97
2 
0.73
6 
0.64
4 
1.33
9 
1.17
2 
4 – 8 
weeks 
4.0 – 5.0 
0.89
5 
0.71
6 
0.79
8 
0.63
8 
0.75
1 
0.60
1 
0.97
2 
0.77
8 
0.64
4 
0.51
6 
1.17
2 
0.93
8 
8 – 16 
weeks 
5.0 – 6.5 
0.71
6 
0.55
1 
0.63
8 
0.49
1 
0.60
1 
0.46
2 
0.77
8 
0.59
8 
0.51
6 
0.39
7 
0.93
8 
0.72
1 
4 – 6 
month
s 
> 6.5 0.551 0.491 0.462 0.598 0.397 0.721 
7 – 12 
month
s 
> 6.5 2 0.791 
 
0.403 2 0.526 2 0.632 2 0.414 2 0.885 
Applied acronyms and description of numbers: bw – body weight. FSMPs - food for special medical purposes; 
MMPs – modified milk products; 1 – initial milk formulas  
(0 – 6 months); 2 – subsequent milk formulas (6-12 months). 
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